Sunday, April 22, 2012

Pressure grows for AstraZeneca's Brennan

David Brennan, the chief executive of AstraZeneca, faces a vote for re-election to the board of the Anglo-Swedish pharmaceutical group at its annual general meeting on Thursday in the face of growing investor pressure for top-level change.


Posted via email from Jack's posterous

No comments: